NCT04426643 is a Phase 1, PHASE2 clinical trial of Autologous adipose-derived mesenchymal stem cells in Urinary Incontinence, sponsored by Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus.

What drugs are being tested in NCT04426643?

Interventions in NCT04426643: Autologous adipose-derived mesenchymal stem cells, Standard treatment according to the Clinical protocols.

What condition does NCT04426643 study?

NCT04426643 studies Urinary Incontinence.

Is NCT04426643 still recruiting?

NCT04426643 is currently completed. Last updated 25 May 2021.

Last reviewed 2021-05-25 · How we verify

NCT04426643

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Urinary Incontinence in Men After Prostatectomy With Autologous Adipose-derived Mesenchymal Stem Cells

Completed Phase 1, PHASE2 Last updated 25 May 2021

What this trial tests

Phase 1, PHASE2 trial testing Autologous adipose-derived mesenchymal stem cells in Urinary Incontinence in 10 participants. Completed in 31 March 2021.

Timeline

1 August 2020

Primary endpoint
20 February 2021

31 March 2021

Quick facts

Lead sponsor	Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 August 2020
Primary completion	20 February 2021
Estimated completion	31 March 2021
Sites	1 location across Belarus

Drugs / interventions tested

Autologous adipose-derived mesenchymal stem cells
Standard treatment according to the Clinical protocols

Conditions studied

Urinary Incontinence — all drugs for Urinary Incontinence →

Sponsor

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

Who can join

Adults 18 to 70, male only, with Urinary Incontinence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Treatment of patients with urinary incontinence after prostatectomy using injection of autologous adipose-derived mesenchymal stem cells mixed with collagen gel

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Advances in the molecular pathogenesis and cell therapy of stress urinary incontinence.
Wang XX, Zhang L, Lu Y. · · 2023 · cited 13× · PMID 36846586 · DOI 10.3389/fcell.2023.1090386

Verify or expand the search:

Other trials of Autologous adipose-derived mesenchymal stem cells

Trials testing the same drug.

NCT03956719 — Treatment of Early Knee Osteoarthritis With Autologous Adipose-derived Mesenchymal Stem Cells · NA · unknown
NCT04446884 — Treatment of Stress Urinary Incontinence in Women With Autologous Adipose-derived Mesenchymal Stem Cells · Phase 1, PHASE2 · completed
NCT04457037 — Treatment of Patients With Trophic Ulcers Using Mesenchymal Stem Cells · Phase 1, PHASE2 · completed

Other recruiting trials for Urinary Incontinence

Currently open trials in the same condition.

NCT07430865 — The RECOVER Study - Postpartum Recovery of Pelvic Floor Structures and the Impact of Early Rehabilitation · NA · recruiting
NCT07105150 — Efficacy of a Video-Based Educational Program on Female Urinary Incontinence · NA · recruiting
NCT07426861 — Pre-Operative Nurse-Led Education With Direct Physiotherapy Referral to Reduce Post-Prostatectomy Incontinence · NA · recruiting
NCT07413692 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and E · NA · recruiting
NCT07413705 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and · NA · recruiting

Other Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus trials

Trials by the same sponsor.

NCT06167564 — Allergy Diagnostic Test Based on Microchip Technology · NA · unknown
NCT05654766 — Assesment of the Functional Activity of Platelets for the Differential Diagnosis of Thrombocytopathies · unknown
NCT05520125 — Treatment of Patients With Bone Tissue Defects Using Mesenchymal Stem Cells Enriched by Extracellular Vesicles · Phase 1, PHASE2 · unknown
NCT05520112 — Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells · Phase 1, PHASE2 · unknown
NCT05214014 — Treatment of Systemic Sclerosis With Autologous Regulatory Т-cells · Phase 1, PHASE2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04426643 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Last refreshed: 25 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04426643.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing